Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination
暂无分享,去创建一个
H. Gevensleben | M. Heikenwalder | A. Heine | P. Brossart | K. Janssen | C. Kurts | P. Knolle | U. Nitsche | N. Garbi | L. Diehl | M. Ringelhan | C. Flores | B. Höchst
[1] Lisa M. Ebert,et al. Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy? , 2017, Clinical & translational immunology.
[2] P. Rosenstiel,et al. Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. , 2016, Immunity.
[3] R. Weissleder,et al. Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. , 2016, Immunity.
[4] L. Zitvogel,et al. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. , 2015, Cancer cell.
[5] F. Ginhoux,et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.
[6] M. Vetizou,et al. Cancer and the gut microbiota: An unexpected link , 2015, Science Translational Medicine.
[7] J. Berzofsky,et al. Vaccine-induced myeloid cell population dampens protective immunity to SIV. , 2014, The Journal of clinical investigation.
[8] C. Meyer,et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab , 2014, Cancer Immunology, Immunotherapy.
[9] Tom C. Freeman,et al. Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation , 2014, Immunity.
[10] F. Marincola,et al. Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment , 2013, Science.
[11] Eric Vivier,et al. The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide , 2013, Science.
[12] Jun Jiang,et al. CpG oligodeoxynucleotide induces bone marrow precursor cells into myeloid-derived suppressor cells. , 2013, Molecular medicine reports.
[13] H. Gevensleben,et al. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. , 2013, Journal of hepatology.
[14] F. Fazio,et al. Clinical and immunologic responses in melanoma patients vaccinated with MAGE‐A3‐genetically modified lymphocytes , 2013, International journal of cancer.
[15] Dung-Tsa Chen,et al. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer , 2013, Cancer Immunology, Immunotherapy.
[16] G. Willimsky,et al. Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer. , 2013, Blood.
[17] C. Loddenkemper,et al. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. , 2013, The Journal of clinical investigation.
[18] D. Klinman,et al. Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells , 2012, The Journal of Immunology.
[19] P. Allavena,et al. Immunology in the clinic review series; focus on cancer: tumour‐associated macrophages: undisputed stars of the inflammatory tumour microenvironment , 2012, Clinical and experimental immunology.
[20] H. Wagner,et al. Chemokines: A New Dendritic Cell Signal for T Cell Activation , 2011, Front. Immun..
[21] M. Manns,et al. Myeloid derived suppressor cells in human diseases. , 2011, International immunopharmacology.
[22] M. Manns,et al. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. , 2011, Blood.
[23] S. Endres,et al. CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice , 2011, Clinical Cancer Research.
[24] E. Kostareli,et al. Efficient Treg depletion induces T‐cell infiltration and rejection of large tumors , 2010, European journal of immunology.
[25] C. Loddenkemper,et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. , 2010, Cancer research.
[26] C. Kurts,et al. Cross-priming in health and disease , 2010, Nature Reviews Immunology.
[27] Thomas Quast,et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell–licensed DCs , 2010, Nature Immunology.
[28] M. Manns,et al. Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC , 2010, Journal of immunotherapy.
[29] M. Manns,et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor , 2009, Hepatology.
[30] P. Sinha,et al. Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1 , 2009, The Journal of Immunology.
[31] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[32] L. Fang,et al. Immunotherapy for advanced melanoma. , 2008, The Journal of investigative dermatology.
[33] B. Lim,et al. Retinoic Acid Increases Foxp3+ Regulatory T Cells and Inhibits Development of Th17 Cells by Enhancing TGF-β-Driven Smad3 Signaling and Inhibiting IL-6 and IL-23 Receptor Expression1 , 2008, The Journal of Immunology.
[34] H. Stein,et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness , 2008, The Journal of experimental medicine.
[35] M. Manns,et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. , 2008, Gastroenterology.
[36] E. Tartour,et al. Analysis and Characterization of Antitumor T-cell Response After Administration of Dendritic Cells Loaded With Allogeneic Tumor Lysate to Metastatic Melanoma Patients , 2008, Journal of immunotherapy.
[37] L. Mariani,et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] D. Neuberg,et al. Long-Lived Antitumor CD8+ Lymphocytes for Adoptive Therapy Generated Using an Artificial Antigen-Presenting Cell , 2007, Clinical Cancer Research.
[39] E. Tartour,et al. Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses , 2006, Clinical Cancer Research.
[40] Bin Yu,et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. , 2003, Cancer research.
[41] D. Gabrilovich,et al. Immature myeloid cells and cancer-associated immune suppression , 2002, Cancer Immunology, Immunotherapy.
[42] V. Barak,et al. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response. , 1992, Immunology letters.
[43] D. Crowther,et al. Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. , 1977, British Journal of Cancer.